• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why Novavax (NVAX) Is Up 10.4% After New XFG-Targeted Nuvaxovid Approvals Expand Partner-Led Reach

    Simply Wall St·09/06/2026 13:21:19
    Listen to the news
    • In August 2026, Novavax announced that its partners secured approvals for the updated Nuvaxovid vaccine targeting the SARS-CoV-2 XFG variant for the 2026–2027 season across the U.S., European Union, and Japan, enabling Novavax to earn royalties and milestones without operating its own commercial infrastructure.
    • A key implication is that Sanofi’s expanded Nuvaxovid promotion in major markets and Takeda’s growing usage in Japan could deepen Novavax’s royalty-based revenue model while reinforcing its partnership-focused operating approach.
    • We’ll now examine how these new XFG-targeted approvals and Sanofi’s broader market push may influence Novavax’s partnership-heavy investment narrative.

    AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    Novavax Investment Narrative Recap

    To own Novavax, you need to believe its royalty and milestone model can offset lumpier product revenue and support a path to consistent profitability. The new XFG-season approvals reinforce that thesis by extending COVID-related royalties without adding commercial costs, but they do not remove the near term risk that partner sales or regulatory timing fall short, especially after the sharp revenue drop in 2026 that keeps liquidity and cash burn squarely in focus.

    Among recent developments, the expanded Sanofi collaboration from May 2025 stands out as most relevant here, because it already set the framework for Sanofi to lead Nuvaxovid commercialization and pursue combination vaccines using Matrix M. The latest XFG approvals now sit on top of that agreement, so any uplift from Sanofi’s broader 2026–2027 season could flow mainly through higher royalties, which ties the near term catalyst closely to partner execution quality rather than Novavax’s own sales force.

    Yet even with new XFG approvals, you still need to weigh the risk that partner driven milestones slip or underperform, something investors should be aware of...

    Read the full narrative on Novavax (it's free!)

    Novavax's narrative projects $348.5 million revenue and $55.9 million earnings by 2028. This implies revenues will decline by 31.4% per year, with earnings decreasing by $366.9 million from $422.8 million today.

    Uncover how Novavax's forecasts yield a $13.78 fair value, a 35% upside to its current price.

    Exploring Other Perspectives

    NVAX 1-Year Stock Price Chart
    NVAX 1-Year Stock Price Chart

    The lowest estimate analysts were far more pessimistic, once modeling revenues falling about 25% annually and questioning whether Matrix M licensing alone can offset weaker vaccine demand worldwide.

    Explore 3 other fair value estimates on Novavax - why the stock might be worth just $13.78!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Seeking Other Investments?

    Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.